GPT and Decreased total neutrophil count: The safety profile of trabectedin plus doxorubicin was similar in pattern with phase I dose-ranging study reporting neutropenia (45%), ALT increase (14%), and thrombocytopenia (17%) as the most common grade 3/4 treatment-emergent adverse events (AEs) [116].